“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Wednesday, August 27, 2025

Acura Pharmaceuticals


Acura Pharmaceuticals — A to Z Product Catalog

  • LTX-03 (LIMITx platform)
    • Type: Immediate-release opioid tablet using LIMITx abuse-deterrent technology
    • Indication: Intended to reduce opioid abuse potential
    • Dose/Form: Investigational; not yet marketed

  • Nexafed® (pseudoephedrine)
    • Generic: Pseudoephedrine
    • Indication: Nasal decongestant (non-prescription cold, sinus, and allergy relief)
    • Dose/Form: Oral tablets—standard pseudoephedrine dosing per OTC guidelines

  • Nexafed® Sinus Pressure + Pain
    • Generic: Acetaminophen + Pseudoephedrine
    • Indication: Relief of sinus pressure, congestion, and associated pain
    • Dose/Form: Oral combination tablets—OTC, per standard dosing

  • Oxaydo® (oxycodone HCl)
    • Generic: Oxycodone hydrochloride
    • Indication: Management of acute and chronic moderate to severe pain (Schedule II opioid)
    • Dose/Form: Oral tablets—abuse-deterrent formulation, dosing per prescribing information

  • VYCAVERT® (hydrocodone bitartrate + acetaminophen)
    • Generic: Hydrocodone + Acetaminophen with abuse-deterrent features
    • Indication: Intended for pain relief but designed to deter misuse
    • Dose/Form: Investigational; abuse-deterrent version, not marketed


    • on

    No comments:

    Post a Comment

    Subscribe to: Post Comments (Atom)